With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.624734-17-4,3-Methoxydihydro-2H-pyran-4(3H)-one,as a common compound, the synthetic route is as follows.
624734-17-4, A mixture of the product from Step A (difluoroacetate, 97.45 mg, 0.136 mmol), 3-methoxydihydro-2H-pyran-4(JH)-one (35.4 mg, 0.272 mmol), 4A molecular sieves (60 mg) and TEA (0.19 mL, 1.36 mmol) in DCM (4 mL) was stirred at rt for 2 h, followed by addition of sodium triacetoxyborohydride (46.12 mg, 0.218 mmol). The resulting mixture was stirred at rt overnight. The reaction was quenched by addition of saturated NaHCOs aqueous solution, extracted with DCM, dried over Na2S04. After removal of solvent, the residue was purified by column chromatography (eluent: 5% 7N NH3 in MeOH in DCM) to give the product as a yellow foam. 1H-NMR (400 MHz, CDCI3): delta 1.56 – 2.12 (m, 7 H), 2.31 (br. s., 1 H), 2.55 – 2.67 (m, 1 H), 3.06 – 3.21 (m, 3 H), 3.24 – 4.16 (m, 14 H), 4.71 (br. s., 2 H), 5.12 (s, 2 H), 7.29 – 7.44 (m, 5 H), 7.69 (br. s., 1 H), 8.72 (br. s., 1 H); LC/MS: C3iH37F3N405: m/z 603.0 (M+H).
The synthetic route of 624734-17-4 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; JANSSEN PHARMACEUTICA NV; CAI, Chaozhong; MCCOMSEY, David F.; SUI, Zhihua; KANG, Fu An; WO2014/14901; (2014); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics